Αποτελέσματα Αναζήτησης
Losartan (Cozaar) is an angiotensin AT1 receptor antagonist. It is approved in numerous countries for the treatment of hypertension and has been approved in the UK, the US and several European countries for stroke risk reduction in patients with hypertension and left ventricular hypertrophy (LVH).
- Losartan - StatPearls - NCBI Bookshelf - National Center for ...
In hypertension with left ventricular hypertrophy, losartan...
- Impact of losartan on stroke risk in hypertensive patients in ... - PubMed
The angiotensin II type 1 receptor antagonist (angio-tensin...
- Losartan - StatPearls - NCBI Bookshelf - National Center for ...
6 Δεκ 2004 · The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the β-blocker atenolol.
26 Φεβ 2024 · In hypertension with left ventricular hypertrophy, losartan inhibits angiotensin II-induced cardiac remodeling, consequently reducing the risk of stroke in these patients. This activity reviews the use of losartan, including indications, mechanism of action, contraindications, pharmacokinetics, adverse event profiles, eligible patient ...
7 Μαρ 2020 · Results: There was a positive effect of Sartans on ischemic stroke in both preclinical and clinical settings (attenuating ischemic brain damage, reducing cerebral inflammation and infarct size, increasing cerebral blood flow).
The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to decrease stroke risk in hypertensive patients to a substantially greater extent than conventional therapy.
25 Μαΐ 2007 · The 36% RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan‐based treatment is more effective than an atenolol‐based treatment for patients with ISH and a high risk for stroke.
1 Σεπ 1996 · Losartan prevented the development of hypertension and left ventricular hypertrophy. Cardiac function measured ex vivo in isolated perfused hearts was improved, as demonstrated by significant increases in left ventricular pressure (22.4%), differentiated left ventricular pressure (dP/dt max) (35.1%), and coronary flow (38%).
